Search
Institutions of higher education have increasingly become the targets of the plaintiffs' class action bar, but many institutions named as defendants in those class actions are finding themselves in that position for the first time. This seminar reviewed the types of class claims being asserted...
Earlier this month, the U.S. Department of Health and Human Services (“HHS”) Office for Civil Rights (“OCR”) announced two (2) different settlements, one with a HIPAA business associate for $350,000 and one with a HIPAA-covered entity pursuant to the OCR Right of Access Initiative for $15,000...
On April 27, 2023, Saul Ewing LLP hosted the first annual Connector’s Conference: Focus on Food, Beverage and Agribusiness at the Minneapolis Club in downtown Minneapolis. The conference featured agribusiness leaders, operators, dealmakers, legal experts and technology innovators who gathered to...
Partner Jonathan Havens will co-chair the 2023 FDLI Annual Conference. As the premier conference for the food and drug law community, the FDLI Annual Conference addresses complex legal, regulatory, compliance, and policy issues in all facets of the FDA-regulated industry. The conference provides in...
Saul Ewing LLP's first annual Connectors Conference: Focus on Food, Beverage & Agribusiness. This half-day event provided an opportunity to connect with and learn from leaders in the food, beverage and agribusiness sector. Our event featured a notable group of speakers, from organizations including...
The use of artificial intelligence (AI) in health care, and specifically, as the utilization of software in medical devices continues to increase. Machine learning (ML) is a branch of AI in which computer systems automatically adapt, improve, and make predictions by applying algorithms to analyze...
Work Product Protection for Patient Safety Information Charles Kelly, MS, partner, at Saul Ewing LLP, will walk attendees through two important pieces of legislation that protect healthcare workers: the Patient Safety and Quality Improvement Act of 2005, which ensures federal privilege and...
On December 2, 2022, the Office for Civil Rights (“ OCR”) and the Substance Abuse and Mental Health Services Administration (“ SAMHSA”) within the U.S. Department of Health and Human Services (“ HHS”) issued a Notice of Proposed Rulemaking (“ NPRM”) to revise the Confidentiality of Substance Use...
In this engaging and useful session, Mr. Havens will use facts from recent food and beverage cases and recent instances of enforcement to provide practical takeaways to help the industry comply with applicable requirements and take defensible positions when developing food labels and product claims.
In this engaging and useful session, Mr. Havens will use facts from recent food and beverage cases and recent instances of enforcement to provide practical takeaways to help the industry comply with applicable requirements and take defensible positions when developing food labels and product claims.
In this engaging and useful session, Mr. Havens will use facts from recent food and beverage cases and recent instances of enforcement to provide practical takeaways to help the industry comply with applicable requirements and take defensible positions when developing food labels and product claims.
In this engaging and useful session, Mr. Havens will use facts from recent food and beverage cases and recent instances of enforcement to provide practical takeaways to help the industry comply with applicable requirements and take defensible positions when developing food labels and product claims.
Kathryn Doyle, a partner at Saul Ewing, will present during the Penn Medicine Commercialization Speaker Series. She will discuss the latest trends in Life Sciences intellectual property on November 17 from 12:00 - 1:00 p.m.
MAKING SENSE OF PRES. BIDEN’S CANNABIS REFORM STATEMENT – FDA’S ROLE IN SCHEDULING EVALUATION Jonathan Havens, Co-Chair of the firm's Cannabis Practice, will discuss President Biden’s recent cannabis reform announcement, its implications for various stakeholders, and FDA’s role in evaluating how...